APEN News and Press, Apollo Endosurgery Inc. From 11/01/22

Grew global revenue 20% GAAP, 24% in constant currency Received FDA authorization for Apollo ESG TM and Apollo REVISE TM systems for treating patients with obesity AUSTIN, TX / ACCESSWIRE / November 1, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in l...

AUSTIN, TX / ACCESSWIRE / October 18, 2022 / Apollo Endosurgery, Inc. ("Company" or "Apollo") (NASDAQ:APEN), a global leader in next-generation minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release financial...

K. Todd Newton Appointed as Interim Chief Executive Officer, Replacing Timothy R. Wright, Effective Immediately MARIETTA, Ga., Sept. 06, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental...

Patients undergoing ESG achieved 24% total body weight loss in a bariatric surgery practice in a community setting. AUSTIN, TX / ACCESSWIRE / August 31, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal a...

Apollo Endosurgery, Inc. (APEN) Q2 2022 Earnings Conference Call August 2, 2022 16:30 ET Company Participants Matt Kreps - Investor Relations Chas McKhann - Chief Executive Officer Jeff Black - Chief Financial Officer Conference Call Participants Chri...

Apollo Endosurgery came in with another strong quarter of top-line growth whilst growing gross margins on the same. The company saw substantial growth in each of its key segments, coupled with regulatory momentum in its Apollo ESG and REVISE series. Valuations are also supportive ...

Apollo Endosurgery press release ( NASDAQ: APEN ): Q2 GAAP EPS of -$0.26 misses by $0.05 . Revenue of $19.3M (+16.2% Y/Y) beats by $1.13M . For further details see: Apollo Endosurgery GAAP EPS of -$0.26 misses by $0.05, revenue of $19.3M beats by $1.13M ...

Grew global revenue 16% (20% in constant currency) as adoption increased across all product lines Secured FDA marketing authorization for Apollo ESG TM and Apollo REVISE TM AUSTIN, TX / ACCESSWIRE / August 2, 2022 / Apollo Endosurgery, Inc. ("Apollo") (Nasdaq:APEN), a global lead...

Publication of MERIT Study Follows FDA Market Authorization of Apollo ESG™ AUSTIN, TX / ACCESSWIRE / July 29, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, announced t...

AUSTIN, TX / ACCESSWIRE / July 21, 2022 / Apollo Endosurgery, Inc. ("Company" or "Apollo") (NASDAQ:APEN), a global leader in next-generation minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release financial re...